May 10 (Reuters) - Novavax Inc said on Monday its combined flu and COVID-19 vaccine produced functional antibodies against influenza and the coronavirus in a preclinical study. (https://refini.tv/3bg25TM) (Reporting by Mrinalika Roy in Bengaluru; Editing by Amy Caren Daniel)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.29 USD | -2.61% | +8.51% | +225.52% |
05:27pm | B. Riley Boosts Price Target on Novavax to $29 From $11, Maintains Buy Rating | MT |
05-21 | Novavax: 1st shipment of R21/MatrixM malaria vaccine | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+225.52% | 2.2B | |
+64.28% | 62.59B | |
-1.08% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.41% | 26.21B | |
-21.53% | 19.09B | |
+4.91% | 13.08B | |
+25.72% | 12.26B | |
+28.81% | 12.05B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax : combined influenza/COVID-19 vaccine shows promise in preclinical study